Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotech Jim who wrote (1985)	12/14/2016 12:59:21 PM
From: Miljenko Zuanic	Read Replies (2) \| Respond to of 3559

M.Yee is regular BULLSHITER like any other sell-side/by-side analyst. < Finally, there are concerns about sarilumab and dupilumab approval but that is due to potential manufacturing delays so not as big a deal and dupilumab could still be approved by its March PDUFA.> Manufacturing delays/overhead for 2017 is much bigger than any 5-later gain for Fovista. Do they have secondary sterile/injectable facility approved/certifies for Sur/Dup production???? Ireland facility was only certified for API, Sanofi new Belgium facility (that they intend to upgrade for biologic is further down the line,....), so if they can not FIX fungal contamination on production line (or any other issue that FDA cited them)....we can see signification delay in Sur/Dup lunch...NO grow in 2017. Hope they have something good to say at JPM. I am growing extremely frustrated with their efforts so far!